Ardelyx(NASDAQ) ARDX

Market Cap$988.12M

Since IPO (2014)-72%

5 Year+150%

1 Year-22%

1 Month-26%

$3.94

-1.63%

-0.07Today

Ardelyx last closing stock price
Metric	Price	Date
Last close	USD 4.00	2026-08-07

Ardelyx stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-19.19%	USD 4.95	2026-07-31
1 month	-26.34%	USD 5.43	2026-07-08
3 month	-41%	USD 6.78	2026-05-08
Year to date	-31.39%	USD 5.83	2025-12-31
1 year	-22.18%	USD 5.14	2025-08-07
3 year	+3.09%	USD 3.88	2023-08-08
5 year	+150%	USD 1.60	2021-08-06
Since inception	-71.65%	USD 14.11	2014-06-19

Ardelyx Financials at a Glance

Market Cap

$988.12M

Revenue (TTM)

$450.89M

Net Income (TTM)

-$55.70M

EPS (TTM)

-$0.23

P/E Ratio

-17.69

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$3.94

Volume

3,025,505.225

Open

$4.05

Price

$3.94

Volume

3,025,505.225

Open

$4.05

Previous Close

$4.00

Daily Range

$3.94 - $4.12

52-Week Range

$3.90 - $8.40

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$3.94

Volume

3,025,505.225

Open

$4.05

Previous Close

$4.00

Daily Range

$3.94 - $4.12

52-Week Range

$3.90 - $8.40

Estimated Earnings Date

Aug 6, 2026

ARDX News

Page 1

ARDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ardelyx

Ardelyx makes medicines for people with gut and kidney problems. These drugs help adults manage painful stomach issues and complex mineral levels. The company focuses on creating treatments that work locally in the intestines.

Treating the Gut and Kidneys

IBSRELA: Oral medicine for adults with irritable bowel syndrome with constipation; this condition involves stomach pain and difficulty passing stool.
XPHOZAH: Therapy used to lower high phosphorus levels in adults on kidney dialysis.
RDX10531: Next-generation inhibitor currently under development for multiple medical uses.
Discovery Assets: Early programs targeting potassium and electrolyte disorders in patients with heart or kidney disease.

Global Partners and New Trials

Partnered with Knight Therapeutics to bring tenapanor to the Canadian market in March 2021.
Formed a deal with Kyowa Kirin in Japan to launch PHOZEVEL for kidney patients in February 2024.
Announced approval for tenapanor in China through a license with Fosun Pharmaceutical in February 2025.
Started a Phase 3 clinical trial in January 2026 to test tenapanor for chronic idiopathic constipation.
Licensed a portfolio of TGR5 agonist compounds to METiS for therapeutic development.

Stopping Absorption at the Source

Ardelyx uses a specific mechanism that stops phosphate absorption at its primary entry point in the body. The company controls a patent portfolio with seven U.S. patents protecting its lead drug until at least 2029.

The 2025 Financial Story

Revenue reached $125.2 million in Q4 2025, up 7.8% from $116.1 million in Q4 2024.
Gross profit was $111.7 million in Q4 2025, a 14.1% increase year-over-year.
Net income turned negative at a loss of $407,000 in Q4 2025, down 108.8% from a profit in Q4 2024.
Free cash flow hit $20.6 million in Q4 2025, up 123.4% from $9.2 million in Q4 2024.
Cash and short-term investments totaled $264.7 million at the end of 2025, up 5.8% from the previous year.

Bottom Line

Ardelyx has transitioned from a research firm to a commercial company selling treatments for chronic conditions. Its focus on specialized partnerships and expanding drug uses supports its position in the biotechnology sector.

AI Generated • Apr 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

489

CEO

Mike Raab

Website

www.ardelyx.com

Headquarters

Waltham, MA 02451, US

ARDX Financials

Key Financial Metrics (TTM)

Gross Margin

93.96%

Operating Margin

-7.86%

Net Income Margin

-12.35%

Return on Equity

-36.00%

Return on Capital

-10.82%

Return on Assets

-9.67%

Earnings Yield

-5.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$988.12M

Shares Outstanding

247.03M

Volume

3.03M

Avg. Volume

3.88M

Financials (TTM)

Gross Profit

$423.67M

Operating Income

-$35.45M

EBITDA

-$23.78M

Operating Cash Flow

-$49.56M

Capital Expenditure

-$668.00K

Free Cash Flow

-$50.23M

Cash & ST Invst.

$281.83M

Total Debt

$256.19M

Ardelyx Performance Analysis

Ardelyx annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 52,158,000	416.6%
2023	2023-12-31	USD 124,456,000	138.6%
2024	2024-12-31	USD 333,615,000	168.1%
2025	2025-12-31	USD 407,320,000	22.1%

Ardelyx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	13.0%
Q4	2025-12-31	13.5%
Q1	2026-03-31	-24.6%
Q2	2026-06-30	27.9%

Ardelyx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.42	-72.1%
2023	2023-12-31	USD -0.30	-28.9%
2024	2024-12-31	USD -0.17	-44.8%
2025	2025-12-31	USD -0.26	53.6%

Ardelyx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	95.0%
Q4	2025-12-31	57.5%
Q1	2026-03-31	-8723.5%
Q2	2026-06-30	53.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$120.88M

+23.8%

Gross Profit

$115.12M

+36.0%

Gross Margin

95.24%

N/A

Market Cap

$988.12M

N/A

Market Cap/Employee

$2.02M

N/A

Employees

489

N/A

Net Income

-$16.72M

+12.4%

EBITDA

-$10.14M

+14.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$281.83M

+18.2%

Total Debt

$256.19M

+24.0%

Accounts Receivable

$100.35M

+60.4%

Inventory

$25.86M

+16.1%

Long Term Debt

$254.65M

+23.9%

Short Term Debt

$1.55M

+30.7%

Return on Assets

-9.67%

N/A

Return on Invested Capital

-7.99%

N/A

Free Cash Flow

-$38.72M

-49.0%

Operating Cash Flow

-$38.64M

-52.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

WVEWave Life Sciences Ltd.

WVEWave Life Sciences Ltd.$6.07-0.49%

NTLAIntellia Therapeutics, Inc.

NTLAIntellia Therapeutics, Inc.$12.10+1.30%

MAZEMaze Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.$26.79-6.49%

UPBUpstream Bio, Inc.

UPBUpstream Bio, Inc.$7.44+2.67%

ZYMEZymeworks Inc.

ZYMEZymeworks Inc.$23.57+0.13%

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$32.27-1.34%

PHVSPharvaris N.V.

PHVSPharvaris N.V.$34.84-0.21%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$132.90-0.00%

ACHRArcher Aviation

ACHRArcher Aviation$6.10+0.09%

NVDANvidia

NVDANvidia$217.51-0.03%

INTCIntel

INTCIntel$99.84-0.02%

ONDSOndas

ONDSOndas$9.21+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.14+0.00%

SMCISuper Micro Computer

SMCISuper Micro Computer$31.82+0.02%

Questions About ARDX

What is the current price of Ardelyx?

Ardelyx is trading at $3.98 per share.

What is the 52-week range for Ardelyx?

Over the past 52 weeks, Ardelyx has traded between $3.90 and $8.40.

How much debt does Ardelyx have?

As of the most recent reporting period, Ardelyx reported total debt of $256.19M.

How much cash does Ardelyx have on hand?

Ardelyx reported $97.19M in cash and cash equivalents in its most recent financial results.

What is Ardelyx’s dividend yield?

Ardelyx does not currently have a dividend yield.

Ardelyx(NASDAQ) ARDX

Ardelyx Financials at a Glance

ARDX News

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Ardelyx Q2 Revenue Jumps 33%

Ardelyx Tops Estimates as Sales Surge

Ardelyx Surpasses Q3 Revenue Estimates

Why Ardelyx Stock Soared Today

Why Ardelyx Stock Popped Today

ARDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ardelyx

Treating the Gut and Kidneys

Global Partners and New Trials

Stopping Absorption at the Source

The 2025 Financial Story

Bottom Line

ARDX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ardelyx Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARDX

What is the current price of Ardelyx?

What is the 52-week range for Ardelyx?

How much debt does Ardelyx have?

How much cash does Ardelyx have on hand?

What is Ardelyx’s dividend yield?

Premium Investing Services